argenx Acquisition of Forte Biosciences Highlights Strategic Expansion in Immunology With $2.2 Billion Deal
Market Chameleon (Mon, 27-Jul 9:52 AM)
argenx Acquires Forte Biosciences for $2.2 Billion, Expanding Its Immunology Pipeline with First-in-Class FB102
Market Chameleon (Mon, 27-Jul 7:05 AM)
FB102 Delivers Statistically Significant Improvements in Vitiligo at 24 Weeks, Backed by Strong Safety Profile
Market Chameleon (Fri, 10-Jul 10:30 AM)
Forte Biosciences’ FB102 Shows Statistically Significant and Durable Benefit in Vitiligo—Efficacy Persists 12 Weeks After Treatment Ends
Market Chameleon (Thu, 9-Jul 10:29 AM)
FBRX’s FB102 Shows Continued Improvement in Vitiligo After Treatment—Data Points to Strong Efficacy and Favorable Safety
Market Chameleon (Thu, 9-Jul 8:36 AM)
